Shares of XOMA Royalty Corp. (XOMA) have gained nearly 60% year-to-date and trade around $29.
XOMA Royalty operates as a biotech royalty aggregator, acquiring the economic rights to potential milestone and royalty payments associated with pre-commercial clinical candidates and commercial therapies from biotech companies. In return, the seller receives non-dilutive, non-recourse funding to further develop their internal drug candidates.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com